Sharps Technology (NASDAQ:STSS – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Analyst Ratings
This is a summary of current ratings and target prices for Sharps Technology and Capricor Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sharps Technology | 1 | 0 | 0 | 0 | 1.00 |
| Capricor Therapeutics | 1 | 0 | 9 | 0 | 2.80 |
Capricor Therapeutics has a consensus price target of $48.36, indicating a potential upside of 65.97%. Given Capricor Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Sharps Technology.
Risk & Volatility
Profitability
This table compares Sharps Technology and Capricor Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sharps Technology | N/A | -157.91% | -154.40% |
| Capricor Therapeutics | N/A | -59.27% | -48.65% |
Valuation & Earnings
This table compares Sharps Technology and Capricor Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sharps Technology | $396,900.00 | 196.20 | -$282.50 million | ($1.63) | -1.13 |
| Capricor Therapeutics | $22.27 million | 75.77 | -$105.04 million | ($2.32) | -12.56 |
Capricor Therapeutics has higher revenue and earnings than Sharps Technology. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 1.2% of Sharps Technology shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Capricor Therapeutics beats Sharps Technology on 9 of the 13 factors compared between the two stocks.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for Sharps Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sharps Technology and related companies with MarketBeat.com's FREE daily email newsletter.
